Published online Mar 18, 2015. doi: 10.5312/wjo.v6.i2.269
Peer-review started: April 30, 2014
First decision: June 27, 2014
Revised: July 7, 2014
Accepted: October 14, 2014
Article in press: October 16, 2014
Published online: March 18, 2015
Core tip: Demineralized bone matrix (DBM) is an allograft product that was found to be safe as an option of bone grafting. As far as its effectiveness is concerned, and according to the existing literature: (1) there is a good evidence for its use in bone cysts combined with autologous marrow aspirate; (2) in fracture nonunion and filling the defects after tumor surgery DBM used alone or combined with other grafting material are supported by a lower quality studies; and (3) there is insufficient evidence to make a treatment recommendation for DBM use in fracture treatment of other applications. Furthermore, according to the existing literature there are results of clinical use of only a few DBM products and thus the recommendation concerning the DBM use should probably also be referred to these specific products and not to any DBM product.